497 Updated results from a phase 1 study of evalstotug (BA3071), an anti–CTLA-4 conditionally active biologic, with or without nivolumab, in advanced solid tumors

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

Regular and Young Investigator Award Abstracts

Topics

Computer Science

Cancer Oncology

Chemistry

Medicine

Immunology

Show all topics

DOI

10.1136/jitc-2024-sitc2024.0497

License

CC-BY-NC

Other Formats

PDF